Large community study suggests simple blood tests could help identify dementia risk earlier in Latino populations disproportionately affected by diabetes and limited health care access.

An international team of researchers has identified a promising new approach for treating infections with the Hepatitis E virus (HEV). At the center of the study is the drug Apilimod, which specifically blocks the entry of the virus into human liver cells, thereby preventing infection at an early stage. The compound targets a mechanism of the host cell, reducing the likelihood that the virus will develop resistance. Apilimod has already been clinically evaluated, which could accelerate its development into a drug against hepatitis E. The study, lead by the Department of Molecular and Medical Virology at Ruhr University Bochum, Germany, was published in the journal eGastroenterology on March 31, 2026.

Temporomandibular joint (TMJ) osteoarthritis affects millions of people, yet the earliest molecular events behind the disease remain poorly understood. Researchers have now mapped how mechanical stress and disk displacement trigger cellular changes in the jaw joint’s synovium using advanced transcriptomic technologies. Their findings reveal inflammatory and fibrotic responses that may drive disease onset. The work provides a high-resolution cellular atlas of TMJ tissues, offering insights that could guide future therapies aimed at preventing joint degeneration.

Leveraging publicly available data from the Global Burden of Disease 2021 (GBD 2021) study, researchers demonstrate a critical epidemiological divergence: despite declining global age-standardized incidence rates of ischemic heart disease (IHD), absolute case counts, mortality, and total disease burden continue to escalate. This growth, largely attributable to population expansion and aging, signals a structural shift in the global cardiovascular burden and poses substantial challenges for sustainable prevention strategies.